<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00903188</url>
  </required_header>
  <id_info>
    <org_study_id>2007-005844-26</org_study_id>
    <nct_id>NCT00903188</nct_id>
  </id_info>
  <brief_title>Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation</brief_title>
  <acronym>CISTCERT</acronym>
  <official_title>Impact of Cyclosporine or Steroid Withdrawal at 3 Months Post Transplantation on Graft Function, Patient Survival and Cardiovascular Surrogate Markers the First 5 Years After Renal Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Liege</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to determine whether steroid withdrawal or calcineurin inhibitor
      withdrawal is superior for graft function and graft survival. Secondary endpoints for this
      study are: incidence of tumors and cardiovascular events.

      The primary objective: To assess if superior graft function (glomerular filtration rate (GFR)
      difference of 10 ml/min) will be achieved at 1 year after transplantation in cohorts of de
      novo kidney transplant patients treated with Myfortic-everolimus plus steroids compared to
      Myfortic-cyclosporine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology:

        -  A 5-year, multicentre, prospective, randomized, open-label, controlled study

             -  Group 1: Simulect + cyclosporine + Myfortic + steroid stop at 3 months

             -  Group 2: Simulect + cyclosporine (decrease dose in one week at month 3 and replace
                by everolimus) + Myfortic + steroid maintenance.

        -  In both groups MPA AUC monitoring will be done at 5-7 days and at 3 months, to ensure
           sufficient MPA protection.

      Sample size calculations:

      A total of 152 patients will be randomized (76 patients per group)

      Population:

      De novo kidney transplant recipients.

      Study duration:

      1.5 years inclusion+ follow-up during the first 5 years
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess if superior graft function (GFR difference of 10 ml/min) will be achieved at 1 year after transplantation in cohorts of de novo kidney transplant patients treated with Myfortic-everolimus plus steroids compared to Myfortic-cyclosporine.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the evolution of graft function (estimated GFR by means of modified MDRD formula)during the first 5 years post transplantation.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>Cyclosporine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Simulect + cyclosporine + Myfortic + steroid stop at 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Simulect + cyclosporine (decrease dose in one week at month 3 and replace by Everolimus (Certican)) + Myfortic + steroid maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Cyclosporine (Group 1):
basiliximab dose: 1x20 mg IV on Day 0 and 1x20 mg IV on Day 4
Cyclosporine: 8 mg/kg PO given before surgery, followed by 2x4 mg/kg/d. C-0h levels: month 1: 150-250 ng/ml; month 2: 100-200 ng/ml; month 3: withdrawal steroids: 100-150 ng/ml.
C-2h levels: month 1: 900-1100 ng/ml; month 2: 800-1000 ng/ml; month 3: withdrawal steroids: maintain level of 750 ng/ml
Enteric-coated mycophenolate(MPA):720mg PO pre-operatively followed by 1.44 g/day.
Steroids: pre-operatively: 250mg methylprednisolone IV; day 1:125mg IV.
Methylprednisolone:day 2-30:PO 12mg/d; day 31-60:tapered to 8mg/d ,day 61-90 :4mg/d; Month 3:stop</description>
    <arm_group_label>Cyclosporine</arm_group_label>
    <other_name>Neoral</other_name>
    <other_name>Myfortic</other_name>
    <other_name>Solumedrol</other_name>
    <other_name>Medrol</other_name>
    <other_name>Simulect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus (Group 2):
Basiliximab dose: idem as in group 1
Cyclosporine: first three months idem group 1; month 3: decreased dose by 50%, simultaneously initiate everolimus at a starting dose of 0.75 mg bid.
Once the everolimus blood levels range 6 - 12 ng/ml, cyclosporine will be stopped.
Enteric-coated mycophenolate (MPA) dosing idem as group 1.
Everolimus starting dose: 0.75 mg bid, trough levels: 6-12 ng/ml.
Steroid dosing: idem group 1, but maintained at 4 mg methylprednisolone after day 60.</description>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>Certican</other_name>
    <other_name>Neoral</other_name>
    <other_name>Myfortic</other_name>
    <other_name>Solumedrol</other_name>
    <other_name>Medrol</other_name>
    <other_name>Simulect</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female recipients of a de novo kidney transplant, aged above 18 years

          -  Women of childbearing potential must have a negative serum or urine pregnancy test
             with sensitivity equal to at least 50 mIU/ml

          -  Patients must be capable of understanding the purpose and risks of the study, and must
             sign an informed consent form

        Exclusion Criteria:

          -  Multiple organ transplantation (e.g., Kidney-pancreas, kidney-heart, kidney-
             liver,...)

          -  Transplantation of a patient who got another organ transplant previously

          -  Recipients of a HLA-identical living-related renal transplant

          -  Patients with PRA &gt; 30%, patients who have lost a first graft from rejection within
             two years after transplantation, and African European patients.

          -  Patients with primary renal disease at risk for recurrence: FSGS, MPGN, HUS

          -  Pregnant or lactating women

          -  WBC &lt; 2.5 x 109/l (IU), platelet count &lt; 100 x 109/l (IU), or Hb &lt; 6 g/dl at the time
             of entry into the study

          -  Active peptic ulcer

          -  Severe diarrhea or other gastrointestinal disorder, which might interfere with their
             ability to absorb oral medication, including diabetic patients with previously
             diagnosed diabetic gastroenteropathy

          -  Known HIV-1 or HTLV-1 positive tests

          -  The use of investigational drugs or other immunosuppressive drugs, as those specified
             in this protocol

          -  Patients receiving bile acid sequestrants

          -  Psychological illness or condition, interfering with the patient's compliance or
             ability to understand the requirements of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis Bosmans, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Antwerp - Department Nephrology-Hypertension</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Louis Bosmans, MD/PhD</last_name>
    <phone>+32/3/821 37 92</phone>
    <email>jeanlouis.bosmans@ua.ac.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erasme University Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Abramowicz, MD/PhD</last_name>
      <phone>+32/2/555 35 32</phone>
      <email>dabram@ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Daniel Abramowicz, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Brussels</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Sennesael, MD/PhD</last_name>
      <phone>+32/2/477 60 55</phone>
      <email>Jacques.Sennesael@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Jacques Sennesael, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Louis Bosmans, MD/PhD</last_name>
      <phone>+32/3/821 37 92</phone>
      <email>jeanlouis.bosmans@ua.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Angelika Jurgens, Study Coord.</last_name>
      <phone>+32/3/821 34 21</phone>
      <email>Angelika.Jurgens@uza.be</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Louis Bosmans, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital, Ghent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Peeters, MD/PhD</last_name>
      <phone>+32/9/332 45 13</phone>
      <email>patrick.peeters@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Patrick Peeters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Liege</name>
      <address>
        <city>Li√®ge</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Bonvoisin, MD/PhD</last_name>
      <phone>+32/4/366 82 58</phone>
      <email>catherine.bonvoisin@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Catherine Bonvoisin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2009</study_first_submitted>
  <study_first_submitted_qc>May 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2009</study_first_posted>
  <last_update_submitted>May 15, 2009</last_update_submitted>
  <last_update_submitted_qc>May 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Jean-Louis Bosmans</name_title>
    <organization>University Hospital Antwerp</organization>
  </responsible_party>
  <keyword>Renal Transplantation</keyword>
  <keyword>graft function</keyword>
  <keyword>cardiovascular events</keyword>
  <keyword>malignancy</keyword>
  <keyword>cyclosporin</keyword>
  <keyword>steroids</keyword>
  <keyword>mycophenolate</keyword>
  <keyword>everolimus</keyword>
  <keyword>renal biopsies</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

